Sientra announced predictably grim results for the fourth quarter of 2015 but the Goleta-based breast implant maker also made a surprise acquisition. The embattled company announced March 9 it paid $7 million in cash for the rights to BioCorneum, an advanced silicone gel scar management product, from Enaltus LLC. It also announced a plunge in…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.